Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > This is how existing shareholders should be treated

<< Previous

Bullboard Posts

Next >>

Comment by longterm56on Jan 31, 2021 3:43pm

151 Views

Post# 32432362

RE:RE:RE:RE:RE:RE:RE:This is how existing shareholders should be treated

Here's another place where the dilution stings. A month ago 10% of the shares was ~7.8 million ... now it would require greater than 10 million. Sad ...

-LT

SPCEO1 wrote: I am not there yet and likely will not get there. But there are enough other shareholders on this board that you could band together and call a special meeting without me if you desired to do that. As Jeff poiinted out, you only need 10% of the shares to call a special meeting.

<< Previous

Bullboard Posts

Next >>

Canadian government to fund Electric Royalties portfolio property